Realizing the value of royalties for universities, non-profits, life sciences companies and others
Our Royalty Monetization team is widely recognized as the leader in the highly specialized field of pharmaceutical royalty monetizations (both classic royalty monetizations and synthetic royalty monetizations). The team has been involved in the royalty monetization market from its earliest stages, having handled virtually all the landmark transactions in this unique area, and has advised on numerous royalty monetization transactions with an aggregate value in excess of $10 billion.
Our Royalty Monetization team is especially well-known for its representations of major universities and non-profit institutions in these transactions, but the team also advises all the other principal participants, including purchasers/investors, individual inventors, and life sciences companies. Our deep experience in royalty monetizations has given us an unparalleled understanding of, and familiarity with, the perspectives and requirements of the participants in this novel and growing market and allows us to design structures to successfully and efficiently implement these unique and complex transactions.
As part of this work, we routinely assist clients with worldwide patent and regulatory exclusivity issues, including worldwide patent term extension issues. We also provide expertise in licensing matters specifically relevant to IP and royalty monetization transactions.